The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung

Abstract Background The ex vivo human perfused lung model has enabled optimizing donor lungs for transplantation and delineating mechanisms of lung injury. Perfusate and airspace biomarkers are a proxy of the lung response to experimental conditions. However, there is a lack of studies evaluating bi...

Full description

Bibliographic Details
Main Authors: Aleksandra Leligdowicz, James T. Ross, Nicolas Nesseler, Michael A. Matthay
Format: Article
Language:English
Published: SpringerOpen 2020-09-01
Series:Intensive Care Medicine Experimental
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40635-020-00343-x
id doaj-a08880b4464742ef9ad6e5115079c5bc
record_format Article
spelling doaj-a08880b4464742ef9ad6e5115079c5bc2020-11-25T03:13:17ZengSpringerOpenIntensive Care Medicine Experimental2197-425X2020-09-018111510.1186/s40635-020-00343-xThe endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lungAleksandra Leligdowicz0James T. Ross1Nicolas Nesseler2Michael A. Matthay3Cardiovascular Research Institute, University of California, San FranciscoDepartment of Surgery, University of California, San FranciscoCardiovascular Research Institute, University of California, San FranciscoCardiovascular Research Institute, University of California, San FranciscoAbstract Background The ex vivo human perfused lung model has enabled optimizing donor lungs for transplantation and delineating mechanisms of lung injury. Perfusate and airspace biomarkers are a proxy of the lung response to experimental conditions. However, there is a lack of studies evaluating biomarker kinetics during perfusion and after exposure to stimuli. In this study, we analyzed the ex vivo-perfused lung response to three key perturbations: exposure to the perfusion circuit, exogenous fresh whole blood, and bacteria. Results Ninety-nine lungs rejected for transplantation underwent ex vivo perfusion. One hour after reaching experimental conditions, fresh whole blood was added to the perfusate (n = 55). Two hours after reaching target temperature, Streptococcus pneumoniae was added to the perfusate (n = 42) or to the airspaces (n = 17). Perfusate and airspace samples were collected at baseline (once lungs were equilibrated for 1 h, but before blood or bacteria were added) and 4 h later. Interleukin (IL)-6, IL-8, angiopoietin (Ang)-2, and soluble tumor necrosis factor receptor (sTNFR)-1 were quantified. Baseline perfusate and airspace biomarker levels varied significantly, and this was not related to pre-procurement PaO2:FiO2 ratio, cold ischemia time, and baseline alveolar fluid clearance (AFC). After 4 h of ex vivo perfusion, the lung demonstrated a sustained production of proinflammatory mediators. The change in biomarker levels was not influenced by baseline donor lung characteristics (cold ischemia time, baseline AFC) nor was it associated with measures of experimental epithelial (final AFC) or endothelial (percent weight gain) injury. In the presence of exogenous blood, the rise in biomarkers was attenuated. Lungs exposed to intravenous (IV) bacteria relative to control lungs demonstrated a significantly higher rise in perfusate IL-6. Conclusions The ex vivo-perfused lung has a marked endogenous capacity to produce inflammatory mediators over the course of short-term perfusion that is not significantly influenced by donor lung characteristics or the presence of exogenous blood, and only minimally affected by the introduction of systemic bacteremia. The lack of association between biomarker change and donor lung cold ischemia time, final alveolar fluid clearance, and experimental percent weight gain suggests that the maintained ability of the human lung to produce biomarkers is not merely a marker of lung epithelial or endothelial injury, but may support the function of the lung as an immune cell reservoir.http://link.springer.com/article/10.1186/s40635-020-00343-xBiomarkersEx vivo-perfused lungStreptococcus pneumoniaeARDSLung transplant
collection DOAJ
language English
format Article
sources DOAJ
author Aleksandra Leligdowicz
James T. Ross
Nicolas Nesseler
Michael A. Matthay
spellingShingle Aleksandra Leligdowicz
James T. Ross
Nicolas Nesseler
Michael A. Matthay
The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
Intensive Care Medicine Experimental
Biomarkers
Ex vivo-perfused lung
Streptococcus pneumoniae
ARDS
Lung transplant
author_facet Aleksandra Leligdowicz
James T. Ross
Nicolas Nesseler
Michael A. Matthay
author_sort Aleksandra Leligdowicz
title The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
title_short The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
title_full The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
title_fullStr The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
title_full_unstemmed The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
title_sort endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
publisher SpringerOpen
series Intensive Care Medicine Experimental
issn 2197-425X
publishDate 2020-09-01
description Abstract Background The ex vivo human perfused lung model has enabled optimizing donor lungs for transplantation and delineating mechanisms of lung injury. Perfusate and airspace biomarkers are a proxy of the lung response to experimental conditions. However, there is a lack of studies evaluating biomarker kinetics during perfusion and after exposure to stimuli. In this study, we analyzed the ex vivo-perfused lung response to three key perturbations: exposure to the perfusion circuit, exogenous fresh whole blood, and bacteria. Results Ninety-nine lungs rejected for transplantation underwent ex vivo perfusion. One hour after reaching experimental conditions, fresh whole blood was added to the perfusate (n = 55). Two hours after reaching target temperature, Streptococcus pneumoniae was added to the perfusate (n = 42) or to the airspaces (n = 17). Perfusate and airspace samples were collected at baseline (once lungs were equilibrated for 1 h, but before blood or bacteria were added) and 4 h later. Interleukin (IL)-6, IL-8, angiopoietin (Ang)-2, and soluble tumor necrosis factor receptor (sTNFR)-1 were quantified. Baseline perfusate and airspace biomarker levels varied significantly, and this was not related to pre-procurement PaO2:FiO2 ratio, cold ischemia time, and baseline alveolar fluid clearance (AFC). After 4 h of ex vivo perfusion, the lung demonstrated a sustained production of proinflammatory mediators. The change in biomarker levels was not influenced by baseline donor lung characteristics (cold ischemia time, baseline AFC) nor was it associated with measures of experimental epithelial (final AFC) or endothelial (percent weight gain) injury. In the presence of exogenous blood, the rise in biomarkers was attenuated. Lungs exposed to intravenous (IV) bacteria relative to control lungs demonstrated a significantly higher rise in perfusate IL-6. Conclusions The ex vivo-perfused lung has a marked endogenous capacity to produce inflammatory mediators over the course of short-term perfusion that is not significantly influenced by donor lung characteristics or the presence of exogenous blood, and only minimally affected by the introduction of systemic bacteremia. The lack of association between biomarker change and donor lung cold ischemia time, final alveolar fluid clearance, and experimental percent weight gain suggests that the maintained ability of the human lung to produce biomarkers is not merely a marker of lung epithelial or endothelial injury, but may support the function of the lung as an immune cell reservoir.
topic Biomarkers
Ex vivo-perfused lung
Streptococcus pneumoniae
ARDS
Lung transplant
url http://link.springer.com/article/10.1186/s40635-020-00343-x
work_keys_str_mv AT aleksandraleligdowicz theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT jamestross theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT nicolasnesseler theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT michaelamatthay theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT aleksandraleligdowicz endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT jamestross endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT nicolasnesseler endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
AT michaelamatthay endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung
_version_ 1724647633865146368